cjc 1295 no dac / ipamorelin blend CJC-1295/Ipamorelin Peptide Therapy in Southlake, TX CJC 1295 No DAC +

BACKGROUND AND OBJECTIVES: Activation of ghrelin receptor growth hormone secretagogue receptor (GHS-R) by endogenous or synthetic ligands amplifies pulsatile release of growth hormone (GH) and enhances food intake, very relevant to development and growth

This GHSR activation by Ipamorelin may result in increased GH secretion, which, in turn, might promote protein synthesis, lipolysis, and insulin-like growth factor-1 (IGF-1) production, as suggested by researchers

not tested in humans | | Protocol timing (fasted, pre-sleep) optimizes response | Indirect: inferred from GH pulsatility physiology | | 12-24-week cycle prevents desensitization | Expert opinion

All peptide therapy should be conducted under physician supervision with appropriate laboratory monitoring

Wood ZA et al

Human studies remain limited, but epidemiological data suggest chronic acetaminophen use is associated with increased oxidative stress biomarkers and, in vulnerable populations, liver enzyme elevation